Shanghai Pharmaceuticals Holding Co Ltd (SHPMY)
7.64
+0.16
(+2.14%)
USD |
OTCM |
May 22, 14:14
Shanghai Pharmaceuticals Revenue (Quarterly): 9.804B for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.804B |
| December 31, 2023 | 8.723B |
| September 30, 2023 | 8.971B |
| June 30, 2023 | 9.469B |
| March 31, 2023 | 9.676B |
| December 31, 2022 | 8.065B |
| September 30, 2022 | 9.183B |
| June 30, 2022 | 8.291B |
| March 31, 2022 | 8.951B |
| December 31, 2021 | 8.571B |
| September 30, 2021 | 8.606B |
| June 30, 2021 | 8.301B |
| March 31, 2021 | 7.953B |
| December 31, 2020 | 7.780B |
| September 30, 2020 | 7.677B |
| June 30, 2020 | 6.588B |
| March 31, 2020 | 5.794B |
| December 31, 2019 | 6.523B |
| September 30, 2019 | 6.847B |
| June 30, 2019 | 6.826B |
| March 31, 2019 | 6.815B |
| December 31, 2018 | 5.999B |
| September 30, 2018 | 6.131B |
| June 30, 2018 | 6.200B |
| March 31, 2018 | 5.719B |
| Date | Value |
|---|---|
| December 31, 2017 | 4.811B |
| September 30, 2017 | 4.987B |
| June 30, 2017 | 4.760B |
| March 31, 2017 | 4.807B |
| December 31, 2016 | 4.387B |
| September 30, 2016 | 4.623B |
| June 30, 2016 | 4.656B |
| March 31, 2016 | 4.475B |
| December 31, 2015 | 4.142B |
| September 30, 2015 | 4.457B |
| June 30, 2015 | 4.161B |
| March 31, 2015 | 4.028B |
| December 31, 2014 | 3.850B |
| September 30, 2014 | 4.005B |
| June 30, 2014 | 3.648B |
| March 31, 2014 | 3.488B |
| December 31, 2013 | 3.311B |
| September 30, 2013 | 3.157B |
| June 30, 2013 | 3.107B |
| March 31, 2013 | 3.145B |
| December 31, 2012 | 2.707B |
| September 30, 2012 | 2.755B |
| June 30, 2012 | 2.676B |
| March 31, 2012 | 2.637B |
| December 31, 2011 | 2.298B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
5.794B
Minimum
Mar 2020
9.804B
Maximum
Mar 2024
8.130B
Average
8.296B
Median
Revenue (Quarterly) Benchmarks
| Sinovac Biotech Ltd | -- |
| CASI Pharmaceuticals Inc | 3.409M |
| Zai Lab Ltd | 87.15M |
| Gracell Biotechnologies Inc (DELISTED) | -- |
| Adagene Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 215.54M |
| Total Expenses (Quarterly) | 9.427B |
| EPS Diluted (Quarterly) | 0.2935 |
| Enterprise Value | 8.695B |
| Gross Profit Margin (Quarterly) | 11.44% |
| Profit Margin (Quarterly) | 2.20% |
| Earnings Yield | 9.45% |
| Operating Earnings Yield | 23.51% |
| Normalized Earnings Yield | 11.02 |